Drug Trial Radar · NCT05382442
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Oct 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
254
Planned (sponsor's estimate)
Start
Jun 27, 2022
Primary completion
May 15, 2026
Study completion Aug 12, 2028
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- Collaborators
- Summit Therapeutics
- First posted
- May 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK112 with or without AK117 in participants with metastatic colorectal cancer who are not suitable for surgery.
Conditions
- Metastatic Colorectal Cancer
Interventions
AK112Drug
AK112 via intravenous (IV) infusion until disease progression or unacceptable toxicity
AK117Drug
AK117 via intravenous (IV) infusion until disease progression or unacceptable toxicity
OxaliplatinDrug
Oxaliplatin via IV infusion
CapecitabineDrug
Capecitabine via oral,The total daily dose was 2000mg/sqm, Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days
IrinotecanDrug
Irinotecan via IV infusion
LeucovorinDrug
Leucovorin via IV infusion
5-fluorouracilDrug
5-fluorouracil via IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rates (ORR)Time frame: Up to approximately 2 years
- Number of participants with adverse events (AEs)Time frame: Up to approximately 2 years
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Summit Therapeutics Research Site
Los Angeles, California
Summit Therapeutics Research Site
Murrieta, California
Summit Therapeutics Research Site
Fairfax, Virginia
The Sixth Hospital,Sun Yat-sen University
Guanzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.